Beauty Forum Feb23 - Flipbook - Page 22
Revolutionary Study
Proves Efficacy of
Patented Xycrobe™
Technology
Crown Aesthetics unveils a new study in the Journal of Cosmetic
Dermatology showcasing the efficacy of its patented Xycrobe™
technology, formulated to address the often overlooked skin biome.
Xycrobe technology targets certain skin conditions and cosmetic
treatments using an isolated, living strain of skin-relevant bacteria.
Topical skincare products are commonly
formulated using ingredients that address various
elements of the skin. However, there is minimal
consideration for how those formulations impact
the skin’s naturally balanced biome, including the
microbiome.
Xycrobe technology harnesses the power of a
particular strain of Cutibacterium acnes subspecies
defendens (C. acnes defendens), a subspecies of
the most prolific skin-specific bacterial species,
which accounts on average for 89% of the bacteria
in the sebaceous skin follicles, to improve the
health and appearance of the skin by curating and
supporting the right strain within the existing
microbiome.
“The research we present in this paper debunks
numerous myths that have perpetuated for the last
half century or so about what constitutes a healthy
skin microbiome, what role C. acnes strains play in
skin health, and the ability to formulate progressive
topicals with live microbes that might contribute to
a healthier skin biome overall,” says Dr. Thomas
M. Hitchcock, PhD, Chief Science Officer, Crown
Laboratories Inc.
“We firmly believe that Crown Laboratories Inc. is
pioneering the “skin biome care” category with our
extensive research into the skin biome. We aim to
continue to invest in exploring the relationship
between the microbes that live on and in the skin,
and how this new philosophy of formulating topicals
to holistically consider the skin biome may
change how we care for the skin. We believe
Xycrobe technology fulfills the skin biome needs
outlined by our research, and we are very excited to
share this data and the BIOJUVE™ products used
in the clinical study, with the world.”
"Traditionally, the medical focus for topical skincare
products has always been placed on how any given
ingredient may impact the overall health of skin
cells with minimal consideration of how the
ingredients impact the skin’s microflora, or
microbiome,” says Dr. Doris Day, Board Certified
Dermatologist and participant in the research study.
“The proven efficacy of this patented Xycrobe
technology reinforces the idea that the human body
depends on symbiosis. I anticipate this research will
diversify the way in which doctors address the
health and treatment of skin conditions."
